KFMRC Position:
Assistant Professor
Research Unit Coordinator
Proteomics & Structural Biology Unit Fundamental and Applied Biology Group
Specialty: Biotechnology
Degree: Ph.D
Brief Bio:
Dr. Ishfaq Ahmad Sheikh is currently working as an Assistant Professor in King
Fahd Medical Research Center (KFMRC) at King Abdulaziz University (KAU), Jeddah, KSA.
He is the Research Unit Coordinator of the Proteomics and Structural Biology unit of KFMRC, along with he also serves as a member of KFMRC Publishing Committee (KPC). He is also involved in teaching students of Masters programme which has been recently started for the first time in Western Saudi Arabia in Faculty of Applied Medical Sciences, KAU. He had the privilege of being a member of Medical Research Orientation Internship (MROI) training program designed for final year Medical students.
Dr. Sheikh did his Masters in Biotechnology from Jamia Millia Islamia, New Delhi, India.
Concurrent with pursuing his Masters degree, he qualified the National level competition and was awarded the Junior Research Fellowship (NET-JRF). In year 2005, he joined his Ph.D at the Department of Biophysics, All India Institute of Medical Sciences (AIIMS), New Delhi, India. AIIMS hails to be one of India’s premier institutes in the field of Medical Science. During Ph.D, his area of research entailed Structural Biology. He worked on the three dimensional structural determination of Lactoperoxidase and its complexes with different ligands. In the quest for his knowledge and for diversifying his expertise, Dr.
Sheikh transmuted to Ohio State University Medical Centre, United States for his Postdoctoral Fellowship programme immediately after submission of his Ph.D thesis.
During his stay in United States he worked in the area of Cancer Biology. He joined KFMRC in January 2012 after spending two years as a Postdoctoral Fellow in United States.
Dr. Ishfaq Ahmad Sheikh
Email: [email protected]
His goal is to target prevalent diseases of Saudi Arabia. He wants to reap the combined benefits of his Doctoral (Structural Biology) and Postdoctoral (Cancer Biology) studies and integrate them towards the treatment of these diseases by designing inhibitors which can be potential drugs. He would adopt Structural (Crystallographic, computational and other biophysical) and Proteomics approaches for these studies.
Area(s) of Research:
-
Cancer Biology-
DNA Damage Response-
Protein Modeling-
ProteomicsNumber of Publications:
1. Rasool M, Zaigham K, Malik A, Riaz N, Alam R, Manan A, Arooj M, Asif M, Saeed A, Qazi MH, Chaudhary AGA, Iqbal Z, Alqahtani MH, Sheikh IA (2013). Comparative study of alterations in Tri-iodothyronine (T3), Thyroxine (T4) hormone levels in breast and ovarian cancer in local population (Communicated) .
2. Khan KM, Rasool M, Malik A, Arooj M, Masood M, Zahid S, Manan A, Asif M, Qazi MH, Chaudhary AGA, Alqahtani MH, Iqbal Z, Sheikh IA (2013). Evaluation of biochemical markers and malondialdehyde status in patients with thyroid gland dysfunction receiving interferon therapy (Communicated) .
3. Jamsheed Javid, Rashid Mir, Masroor M, Imtiyaz Ahamad, Shazia Farooq, Prasant Yadav, Mariyam Zuberi, Ajaz Ah Bhat, Ishfaq Ahmad Sheikh, Tanveer Khalani, P K Julka, Anant Mohan, Maqbool Lone , P C Ray and Alpana Saxena (2013). TP53 is a Mutational Target in Non Small Cell Lung Cancer Patients and its Pro/Pro Variant is Potentially Contributing to Cancer Susceptibility. J Carcinogene Mutagene (doi: 10.4172/2157- 2518.1000138).
4. Ahmad I, Mir R, Zuberi M, Javid J, Yadav P, Farooq S, M. Masroor, Guru S,
Shahnawaz S, Ray PC, Sheikh IA, Khatlani T, Bhat AA, Gupta N, Jetly S, Ahmad N and Saxena A (2013). Inactivation of RIZ1 Gene by Promoter Hypermethylation is Associated with
Disease Progression and Resistance to Imatinib in Indian Chronic Myelogenous Leukemia Patients, First Study from India. J Cancer Sci Ther. 5.2: 45-51.
5. Dar TA, Sheikh IA, Ganie SA, Ali R, Singh LR, Kamal MA and Zargar MA (2013).
Molecular linkages between Diabetes and Alzheimer's Disease: Current scenario and future prospects. CNS & Neurological Disorders-Drug Targets (in press).
6. Mirza Z, Ali A, Ashraf GM, Kamal MA, Abuzenadah AM, Choudhary AGA, Damanhouri GA and Sheikh IA* (2013). Proteomics approaches to understand linkage between Alzheimer’s disease and Type 2 Diabetes Mellitus. CNS & Neurological Disorders- Drug Targets (in press).
7. Ali R, Kumar S., Naqvi RA, Sheikh IA, Rao DN (2013). Multiple Antigen Peptide consisting of B- and T-cell epitopes of F1 antigen of Y. pestis showed enhanced humoral and mucosal immune response in different strains of mice. Int Immunopharmacol. 15(1): 97- 105.
8. Ali R, Sheikh IA, Jabir NR and Kamal MA (2012). Comparative view of couple of decade’s research on Cholinesterase inhibition. Am. J. Neuroprotec. Neuroregen. 4 (2): 1-8 . (Equal author).
9. Sheikh IA., Ali R, Dar TA., Kamal M.A. (2012) An overview on potential
neuroprotective compounds for management of Alzheimer’s disease. CNS & Neurological Disorders-Drug Targets. 11 (8): 1006-1011.
10. Ishfaq M, Malik A, Faiz M, Sheikh IA, Asif M, Khan MN, Qureshi MS, Zahid S, Manan A, Arooj M, Qazi MH, Chaudhary A, Alqahtani MH, Rasool M (2012). Molecular
characterization of FLT3 mutation in acute leukemia patients. Asian Pac J Cancer Prev. 13(9):
4581-5.
11. Ansari SA, Satar R, Alqahtani MH, Alam F, Ansari SA, Naseer MI, Karim S, Sheikh IA (2012). Cost effective surface functionalization of silver nanoparticles for high yield
immobilization of Aspergillus oryzae β galactosidase and its application in lactose hydrolysis.
Process Biochemistry. 47 (12): 2427-2433.
12. Ali R, Mirza Z, Ashraf GM, Kamal MA, Damanhouri GA, Abuzenadah AM, Chaudhary AGA, Sheikh IA* (2012). New anti cancer agents: Recent development in tumor therapy.
Anticancer Research, 32 (7): 2999-3005. (Corresponding author).
13. Sheikh IA, Singh AK, SinghN, Sinha M, Singh SB, Bhushan A, Kaur P, Srinivasan A, Sharma S, Singh TP (2009). Structural evidence of substrate specificity in mammalian peroxidases: Structure of the thiocyanate complex with lactoperoxidase and its interactions at 2.4 Å resolution. J. Biol. Chem. 284(22): 14849-14856.
14. PrabhakarH, Ali Z, Rath GP, Sheikh IA (2008). Vecuronium Bromide and
Methylprednisolone Succinate are Physically Incompatible. J Neurosurg Anesthesiol 20(2):
153-154.
